Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Mahaffey

Showing results (461-470 of 627) with videos related to

Pageof 63
Sort By:
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|March 31, 2021
Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II)Larry R Jackson, Peter Schrader, Laine Thomas, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 7, 2021
Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID TrialJemi Galani, Hillary Mulder, Frank W Rockhold, et al.
Circulation|November 12, 2023
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and AlbuminuriaBrendon L Neuen, Hiddo J L Heerspink, Priya Vart, et al.
The Lancet. Diabetes & Endocrinology|November 28, 2024
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trialsSunil V Badve, Anika Bilal, Matthew M Y Lee, et al.
European Heart Journal. Acute Cardiovascular Care|August 4, 2016
Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experienceSergio Leonardi, Renato D Lopes, Ph Gabriel Steg, et al.
American Heart Journal|September 21, 2015
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)Sameer Bansilal, Zachary Bloomgarden, Jonathan L Halperin, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 25, 2015
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxarJean-Pierre Déry, Kenneth W Mahaffey, Pierluigi Tricoci, et al.
American Heart Journal|March 21, 2016
Pooled analysis of adverse event collection from 4 acute coronary syndrome trialsAndré Zimerman, Renato D Lopes, Amanda L Stebbins, et al.
Vascular Medicine (London, England)|July 12, 2018
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trialJeffrey S Berger, Beth L Abramson, Renato D Lopes, et al.
Circulation|November 21, 2007
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trialPierluigi Tricoci, Yuliya Lokhnygina, Lisa G Berdan, et al.
Pageof 63

Showing results (461-470 of 627) with videos related to

Sort By:
Pageof 63
American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions|March 31, 2021
Dosing of Direct Oral Anticoagulants in Patients with Moderate Chronic Kidney Disease in US Clinical Practice: Results from the Outcomes Registry for Better Informed Treatment of AF (ORBIT-AF II)Larry R Jackson, Peter Schrader, Laine Thomas, et al.
International Journal of Chronic Obstructive Pulmonary Disease|April 7, 2021
Association of Chronic Obstructive Pulmonary Disease with Morbidity and Mortality in Patients with Peripheral Artery Disease: Insights from the EUCLID TrialJemi Galani, Hillary Mulder, Frank W Rockhold, et al.
Circulation|November 12, 2023
Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and AlbuminuriaBrendon L Neuen, Hiddo J L Heerspink, Priya Vart, et al.
The Lancet. Diabetes & Endocrinology|November 28, 2024
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trialsSunil V Badve, Anika Bilal, Matthew M Y Lee, et al.
European Heart Journal. Acute Cardiovascular Care|August 4, 2016
Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experienceSergio Leonardi, Renato D Lopes, Ph Gabriel Steg, et al.
American Heart Journal|September 21, 2015
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)Sameer Bansilal, Zachary Bloomgarden, Jonathan L Halperin, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 25, 2015
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxarJean-Pierre Déry, Kenneth W Mahaffey, Pierluigi Tricoci, et al.
American Heart Journal|March 21, 2016
Pooled analysis of adverse event collection from 4 acute coronary syndrome trialsAndré Zimerman, Renato D Lopes, Amanda L Stebbins, et al.
Vascular Medicine (London, England)|July 12, 2018
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trialJeffrey S Berger, Beth L Abramson, Renato D Lopes, et al.
Circulation|November 21, 2007
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trialPierluigi Tricoci, Yuliya Lokhnygina, Lisa G Berdan, et al.
Pageof 63